权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Alzheimer's Disease and Related Dementia Care within the Medicare Program

医疗保险计划内的阿尔茨海默病和相关痴呆症护理

基本信息

批准号：
10413262
负责人：
JOHN HSU
金额：
$ 81.51万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-30 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10413262
关键词：
Address Affect Alzheimer&apos s disease related dementia American Antipsychotic Agents Area Attention Benchmarking Caring Cholinesterase Inhibitors Chronic Clinical Clinical Research Code Combined Modality Therapy County Data Data Science Data Set Dementia Diabetes Mellitus Diagnosis Diagnostic Disease Dose Electronic Health Record Enrollment Epilepsy Evaluation Family Fee-for-Service Plans Future Geography Gold Guideline Adherence Guidelines Health Services Accessibility Health system Hypothyroidism Incentives Individual Intervention Life Link Malignant Neoplasms Measures Medical Medicare Medicare claim Modernization Morbidity - disease rate Natural experiment Neurologist Pathway interactions Patient Care Patients Patterns of Care Penetration Physicians Policies Policy Maker Policy Research Population Privatization Process Registries Research Risk Structure Subgroup Testing Therapeutic United States Validation Work apolipoprotein E-4 base beneficiary cost data registry dementia care dual eligible ethnic minority evidence based guidelines family burden flexibility genetic testing improved insurance plan medical specialties novel patient population payment programs racial and ethnic

项目摘要

Abstract: Millions of Americans have Alzheimer's Disease and Related Dementias (“dementia”), with many millions more expected to develop it over the next few decades; dementia is a life-altering condition with high levels of associated morbidity. Most of these patients are Medicare beneficiaries. With new treatments on the horizon, there is both a promise for future improvements and risk because of the potential cost of such treatments combined with growing numbers of patients, especially risk of fiscal strain for patients, families, and the Medicare program (total spending is estimated to reach $1 trillion dollars/year by 2050). Despite the promise and risk, there is limited information about current dementia care within the traditional fee-for-service Medicare program (aka TM), the larger of Medicare's two components (the other component is Medicare Advantage (MA), which is administered by private plans). One major barrier to examining care nationally within the Medicare program is the uncertain validity of dementia diagnoses in claims data. To address these issues, we first will use a novel dataset with individual-level linkages of longitudinal data from a dementia registry, electronic health record, and Medicare claims (2006-17) to predict which patients with dementia-related diagnosis codes have true disease. We then will apply this approach to a national dataset of all TM beneficiaries to identify beneficiaries with dementia (2006-21), assess care patterns, and examine the impact of Medicare policy changes on beneficiaries' receipt of guideline-concordant dementia care. We will exploit a natural experiment in which policy changes shift the distribution of patients in TM vs. MA within each county, i.e., changes in MA penetration because of mandated MA benchmark changes. Prior work has found that MA has better process quality compared to TM for some chronic conditions, e.g., diabetes, and that MA penetration favorably impacts guideline adherence and care in TM for such conditions. We will investigate the effect of MA penetration on dementia care within TM. We have three aims: Aim 1) Validation of a claims-based dementia definition among those who have a dementia diagnosis; Aim 2) Examination of the impact of MA penetration on guideline-concordant diagnostic evaluation for TM dementia patients; and Aim 3) Examination of the impact of MA penetration on guideline-concordant treatments for TM dementia patients. In summary, we will apply modern data science approaches to identify the patients in the Medicare program who have dementia, then examine how changes in the Medicare program affects dementia care within each county in the United States. These Medicare policy changes both help generate evidence and could lend themselves to future interventions to improve dementia care, e.g., through adjustments in Medicare quality incentives. Moreover, these data could help inform patients, families, clinicians, and policy makers about how we can improve care for this rapidly expanding population of patients.

摘要：数以百万计的美国人患有阿尔茨海默病和相关痴呆症（“痴呆症”），预计将在未来几十年内发展;痴呆症是一种改变生活的疾病，相关的发病率。大多数患者都是医疗保险受益人。随着新疗法的出现，这种治疗方法既有未来改进的希望，也有潜在成本带来的风险。加上患者人数不断增加，尤其是患者、家庭和医疗保险计划（到2050年，总支出估计将达到1万亿美元/年）。尽管承诺和风险，在传统的按服务收费的医疗保险中，有关目前痴呆症护理的信息有限。计划（又名TM），Medicare两个组成部分中较大的一个（另一个组成部分是Medicare Advantage (MA)，由私人计划管理）。在全国范围内检查护理的一个主要障碍是，医疗保险计划是索赔数据中痴呆症诊断的不确定有效性。为了解决这些问题，我们首先将使用一种新的数据集，该数据集具有来自痴呆登记处的纵向数据的个体水平联系，电子健康记录和医疗保险索赔（2006-17），以预测哪些患者与痴呆症有关诊断代码有真实的疾病。然后，我们将这种方法应用于所有TM的国家数据集受益人确定受益人与痴呆症（2006-21），评估护理模式，并检查影响关于受益人接受指南一致的痴呆症护理的医疗保险政策变化。我们将利用一个自然实验，其中政策变化改变了每个县内TM与MA患者的分布，也就是说，由于强制性并购基准变更，并购渗透率发生变化。之前的研究发现，MA 对于某些慢性疾病，例如，糖尿病，而MA 渗透有利地影响针对此类条件的TM中的指南依从性和护理。我们将调查 MA渗透对TM内痴呆症护理影响。我们有三个目标：目标1）验证基于索赔的痴呆症诊断者中的痴呆定义;目的2）检查MA的影响对TM痴呆患者的指南一致性诊断评估的渗透;以及目的3）检查 MA渗透对TM痴呆患者指南一致性治疗的影响。总之，我们将应用现代数据科学方法来识别医疗保险计划中的患者，痴呆症，然后检查医疗保险计划的变化如何影响每个县的痴呆症护理，美国的这些医疗保险政策的变化既有助于产生证据，也有助于改善痴呆症护理的未来干预措施，例如，通过调整医疗保险质量激励措施。此外，这些数据可以帮助告知患者，家庭，临床医生和政策制定者我们如何能够为迅速扩大的患者群体提供更好的护理。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Development and Validation of a Deep Learning Model for Earlier Detection of Cognitive Decline From Clinical Notes in Electronic Health Records.

DOI：
10.1001/jamanetworkopen.2021.35174
发表时间：
2021-11-01
期刊：
JAMA network open
影响因子：
13.8
作者：
Wang L;Laurentiev J;Yang J;Lo YC;Amariglio RE;Blacker D;Sperling RA;Marshall GA;Zhou L
通讯作者：
Zhou L

Implementation of quality measures and patient-reported outcomes in an epilepsy clinic.

在癫痫诊所实施质量措施和患者报告的结果。

DOI：
10.1212/wnl.0000000000008548
发表时间：
2019
期刊：
Neurology
影响因子：
9.9
作者：
Moura,LidiaMVR;Magliocco,Brandon;Ney,JohnP;Cheng,EricM;Esper,GregoryJ;Hoch,DanielB
通讯作者：
Hoch,DanielB

Value-Based Prices Could Establish Common Ground on Heart Failure Drug Pricing and Coverage.

基于价值的价格可以为心力衰竭药物的定价和承保范围建立共同点。